These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

136 related articles for article (PubMed ID: 18258341)

  • 21. Lessons for AIDS vaccine development from non-AIDS vaccines.
    Clements-Mann ML
    AIDS Res Hum Retroviruses; 1998 Oct; 14 Suppl 3():S197-203. PubMed ID: 9814944
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Biological considerations in the development of a human immunodeficiency virus vaccine.
    Nathanson N; Mathieson BJ
    J Infect Dis; 2000 Aug; 182(2):579-89. PubMed ID: 10915092
    [TBL] [Abstract][Full Text] [Related]  

  • 23. An HIV vaccine: how and when?
    Esparza J
    Bull World Health Organ; 2001; 79(12):1133-7. PubMed ID: 11799445
    [TBL] [Abstract][Full Text] [Related]  

  • 24. DNA vaccines for HIV: challenges and opportunities.
    Hokey DA; Weiner DB
    Springer Semin Immunopathol; 2006 Nov; 28(3):267-79. PubMed ID: 17031649
    [TBL] [Abstract][Full Text] [Related]  

  • 25. AIDS vaccine development: the long and winding road.
    Garber DA; Feinberg MB
    AIDS Rev; 2003; 5(3):131-9. PubMed ID: 14598562
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Current strategies and limitations of HIV vaccines.
    Kawalekar OU; Shedlock DJ; Weiner DB
    Curr Opin Investig Drugs; 2010 Feb; 11(2):192-202. PubMed ID: 20112169
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Candidate vaccines protect macaques against primate immunodeficiency viruses.
    Stott J; Hu SL; Almond N
    AIDS Res Hum Retroviruses; 1998 Oct; 14 Suppl 3():S265-70. PubMed ID: 9814954
    [TBL] [Abstract][Full Text] [Related]  

  • 28. HIV vaccines: new frontiers in vaccine development.
    Duerr A; Wasserheit JN; Corey L
    Clin Infect Dis; 2006 Aug; 43(4):500-11. PubMed ID: 16838241
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Building collaborative networks for HIV/AIDS vaccine development: the AVIP experience.
    Ferrantelli F; Buttò S; Cafaro A; Wahren B; Ensoli B
    Springer Semin Immunopathol; 2006 Nov; 28(3):289-301. PubMed ID: 16983452
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Innovative approaches to develop prophylactic and therapeutic vaccines against HIV/AIDS.
    Cafaro A; Macchia I; Maggiorella MT; Titti F; Ensoli B
    Adv Exp Med Biol; 2009; 655():189-242. PubMed ID: 20047043
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Human immunodeficiency virus antibodies and the vaccine problem.
    Chiodi F; Weiss RA
    J Intern Med; 2014 May; 275(5):444-55. PubMed ID: 24581142
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Heterologous prime-boost vaccination strategies for HIV-1: augmenting cellular immune responses.
    Newman MJ
    Curr Opin Investig Drugs; 2002 Mar; 3(3):374-8. PubMed ID: 12054082
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Development of an AIDS vaccine: status report].
    Girard MP
    Med Trop (Mars); 2007 Aug; 67(4):340-6. PubMed ID: 17926791
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Replicating viral vectors as HIV vaccines: summary report from the IAVI-sponsored satellite symposium at the AIDS vaccine 2009 conference.
    Excler JL; Parks CL; Ackland J; Rees H; Gust ID; Koff WC
    Biologicals; 2010 Jul; 38(4):511-21. PubMed ID: 20537552
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Update on HIV vaccines.
    Meldorf M; Corey L
    STEP Perspect; 1997; 9(2):5-6, 8-9. PubMed ID: 11364929
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Lessons from HIV-1 vaccine efficacy trials.
    Excler JL; Michael NL
    Curr Opin HIV AIDS; 2016 Nov; 11(6):607-613. PubMed ID: 27537673
    [TBL] [Abstract][Full Text] [Related]  

  • 37. HIV-1 vaccine clinical trials: the Brazilian experience.
    Ersching J; Pinto AR
    Rev Med Virol; 2009 Sep; 19(5):301-11. PubMed ID: 19650156
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Preventive HIV-1 vaccines: where are we going?
    Kent SJ
    Int J STD AIDS; 1998 Dec; 9(12):715-9. PubMed ID: 9874116
    [TBL] [Abstract][Full Text] [Related]  

  • 39. AIDS vaccine: efficacy, safety and ethics.
    Veljkovic V; Veljkovic N; Glisic S; Ho MW
    Vaccine; 2008 Jun; 26(24):3072-7. PubMed ID: 18164521
    [TBL] [Abstract][Full Text] [Related]  

  • 40. HIV preventive vaccines. Progress to date.
    Esparza J; Osmanov S; Heyward WL
    Drugs; 1995 Nov; 50(5):792-804. PubMed ID: 8586027
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.